Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less fluid, fewer complications? trial tests new strategy in liver transplants

NCT ID NCT07695363

Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial compares two ways of managing fluids during liver transplant surgery in adults with end-stage liver disease. One strategy limits fluids and uses medications to maintain blood pressure, while the other gives more fluids to optimize heart function. The goal is to see which approach leads to fewer severe complications and better recovery after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low-splanchnic blood volume restrictive fluid management strategy (with phlebotomy) vs. cardiac output optimized liberal fluid management strategy
What this could lead to
If successful, this could establish a better way to manage fluids during liver transplant surgery, reducing severe complications and improving recovery for patients.
What could go wrong
This is a large trial, but results may not apply to all transplant patients or centers. The restrictive strategy carries risks like low blood pressure or organ strain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 866 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Nov 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult ≥ 18 years old 2. Undergoing liver transplantation (LT) 3. End-stage liver disease (ESLD) (with or without hepatocellular carcinoma) as the indication for transplantation. Exclusion Criteria: 1. Undergoing LT for an indication other than ESLD (e.g., acute liver failure, primary liver cancer without ESLD, retransplantation, amyloid neuropathy, polycystic liver disease, or any other indication not associated with ESLD) 2. Undergoing combined solid organ transplantations 3. Any of the following conditions: * severe chronic renal failure (GFR \< 15 ml/minute/1.73 m2 \[CKD-EPI equation\] or already on renal replacement therapy (RRT)) * severe anemia (hemoglobin level \< 80 g/L) * hemodynamic instability (norepinephrine equivalent \> 10 ug/min) 4. Physician refusal to enroll the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage liver disease (ESLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure End Stage Liver Disease liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage liver disease (ESLD) Liver transplantation (LT)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre hospitalier de l'Université de Montréal (CHUM)

    RECRUITING

    Montreal, Quebec, H2X 0C1, Canada

  • London Health Sciences Centre (LHSC)

    RECRUITING

    London, Ontario, N6G 2V4, Canada

  • McGill University Health Centre (MUHC)

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Vancouver General Hospital (VGH)

    RECRUITING

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.